UroGen Pharma Ltd.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $51.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 2, 2026 | Before market open | $37.84M | $-0.54 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $27.50M | $-0.69 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $24.20M | $-1.05 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | Before market open | $24.60M | $-0.80 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $25.20M | $-0.55 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating expenses | full-year 2026 | $260.00M to $270.00M | Raised |
| non-cash share-based compensation expense | full-year 2026 | $20.00M to $24.00M | Lowered |
| year-over-year growth rate | 2026 | 3% to 7% growth | Maintained |
| net product revenue for JELMYTO | 2026 | $97.00M to $101.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements UroGen Pharma filed with the SEC
UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights
Results of operations · EX-99.1 to Form 8-K
UroGen Reports ZUSDURI ™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
Results of operations · EX-99.1 to Form 8-K
UroGen Announces ZUSDURI TM Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI ™ Launch Gains Momentum
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI ™ and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MARCH 10, 2025
Results of operations · EX-99.1 to Form 8-K
Disclaimers This investor presentation contains forward-looking
Regulation FD disclosure · EX-99.1 to Form 8-K
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and
Material agreement · Other events · EX-99.2 to Form 8-K
Response Results from the ENVISION Study NASDAQ: URGN June 13, 2024 1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Delivers Double Digit JELMYTO ® Growth and Prepares for the Next Phase of the Company
Results of operations · EX-99.1 to Form 8-K
March 2024 For investor audiences only. Not for promotional use with healthcare professionals.
Regulation FD disclosure · EX-99.1 to Form 8-K
February 2024 For investor audiences only. Not for promotional use with healthcare professionals.
Regulation FD disclosure · EX-99.1 to Form 8-K
UroGen Pharma Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
UroGen Announces $120 Million Private Placement of Ordinary Shares
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of ATLAS & ENVISION Studies July 27, 2023 NASDAQ: URGN 1
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
(10.7) Death 0 1 ( 0.7) Patients Censored, n (%) 105 (73.9) 85 (60.7) Hazard Ratio (95% CI) 0.45 (0.29, 0.68) UroGen Data on File 26 Source: Table 14.2.1.1 Full table in Appendix
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Excerpt of Transcript of UroGen Pharma Ltd. Earnings Call Held on March 16, 2023
Results of operations · EX-99.2 to Form 8-K
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
Agreement terminated · Results of operations · EX-99.1 to Form 8-K